Skip to main content

Elutia Inc.

corporate_fare Company Profile

Elutia Inc.

ELUT·NASDAQ·Life Sciences·CIK 0001708527

Elutia develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients by addressing unmet medical needs and reducing complications such as infection, migration, erosion, implant rejection, and fibrosis. The company's operations cover research and development through the commercial distribution of biologic matrix products used in plastic and reconstructive surgery. On October 1, 2025, Elutia divested its cardiac implantable electronic device ("CIED") products, EluPro™ and CanGaroo®, to Boston Scientific Corporation ("BSC") and Cardiac Pacemakers Inc ("CPI") for an aggregate purchase price of up to $88.0 million in cash. EluPro was the first antibiotic-eluting biologic matrix envelope for use with CIEDs. Following this sale, Elutia is focused on advancing its drug-eluting biomatrix ("DEB") platform. This platform utilizes biologic matrix and local drug delivery capabilities to address complications in reconstructive procedures and surgical repair, such as infection, inflammation, and fibrosis. The company's lead development programs include NXT-41, a next-generation biologic matrix, and NXT-41x, which incorporates local antibiotic drug delivery into the NXT-41 matrix. NXT-41 is an advanced biomatrix designed for consistent handling and incorporation, enabling scalable manufacturing.

Elutia Inc. (NASDAQ:ELUT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for ELUT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for ELUT spans 8-K, 10-Q, DEF 14A, 10-K.

Recent high-impact activity:

  • Elutia Posts $1.1M Q3 Sales, Confirms NXT-41x FDA Filing This Quarter With $29.1M Cash
  • Elutia Q3: $1.1M Sales, $29.1M Cash, NXT-41x FDA Filing Set for Q4
  • Elutia Closes SimpliDerm Sale, Receives $7.7M Cash to Fund NXT-41x Launch
  • Elutia Faces Nasdaq Delisting, Secures $15M Loan, and Divests SimpliDerm
  • Elutia Posts Q2 Loss but Says Funding Is in Place Through NXT-41x Launch Without Equity Offering

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$12.29M
Net Income
$53.38M
Diluted EPS
$0.87
Op. Cash Flow
-$44.81M
Free Cash Flow
-$46.69M
Gross Profit
$6.6M
Operating Income
-$26.91M
Cash & Equivalents
$36.35M
Debt / Equity
0.00×
Net Margin
434.2%
Shares Outstanding
41.42M sh
Source: 10-K · filed 2026-03-13 · accession 0001104659-26-027664

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 33,661 shares in ELUT as of the October 30, 2026 settlement, a 119.6% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 15.0% of ELUT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)33,661 shares as of October 30, 2026
Change vs prior period▲ 119.6%
Days to cover1.00 at avg daily volume of 70,790
Daily short volume (FINRA facilities)15.0% of 45,285 shares on November 20, 2026
5-day average short volume23.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with E →
$0.90 -0.01% today
52-week range · as of 2026-11-05 $0.50 – $1.39
Market cap
$39.96M
Volume
83.9K (1.1× avg)
3-mo avg 79.2K
Live data · 2026-11-22 00:56 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ELUT - Latest Insights

ELUT
Nov 05, 2026, 4:17 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7509
Real-time Price: $0.900 info
Change: +$0.1491 (+20%) info
Market Cap: $39.962M info
ELUT
Nov 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7509
Real-time Price: $0.900 info
Change: +$0.1491 (+20%) info
Market Cap: $39.962M info
ELUT
Aug 21, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9509
Real-time Price: $0.900 info
Change: -$0.0509 (-5%) info
Market Cap: $39.962M info
ELUT
Aug 14, 2026, 4:45 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.941
Real-time Price: $0.900 info
Change: -$0.041 (-4%) info
Market Cap: $39.962M info
ELUT
Aug 13, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.871701
Real-time Price: $0.900 info
Change: +$0.028299 (+3%) info
Market Cap: $39.962M info
ELUT
Aug 13, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7914
Real-time Price: $0.900 info
Change: +$0.1086 (+14%) info
Market Cap: $39.962M info
ELUT
Aug 07, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.850
Real-time Price: $0.900 info
Change: +$0.050 (+6%) info
Market Cap: $39.962M info
ELUT
Jul 16, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.9351
Real-time Price: $0.900 info
Change: -$0.0351 (-4%) info
Market Cap: $39.962M info
ELUT
Jun 16, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.900 info
Change: -$0.050 (-5%) info
Market Cap: $39.962M info
ELUT
May 15, 2026, 4:38 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.03
Real-time Price: $0.900 info
Change: -$0.130 (-13%) info
Market Cap: $39.962M info
ELUT
May 15, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.03
Real-time Price: $0.900 info
Change: -$0.130 (-13%) info
Market Cap: $39.962M info
ELUT
May 14, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.00
Real-time Price: $0.900 info
Change: -$0.100 (-10%) info
Market Cap: $39.962M info
ELUT
May 12, 2026, 4:12 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.05
Real-time Price: $0.900 info
Change: -$0.150 (-14%) info
Market Cap: $39.962M info
ELUT
Apr 22, 2026, 5:00 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $1.15
Real-time Price: $0.900 info
Change: -$0.250 (-22%) info
Market Cap: $39.962M info
ELUT
Mar 13, 2026, 4:11 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.08
Real-time Price: $0.900 info
Change: -$0.180 (-17%) info
Market Cap: $39.962M info
ELUT
Mar 11, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.15
Real-time Price: $0.900 info
Change: -$0.250 (-22%) info
Market Cap: $39.962M info
ELUT
Mar 09, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.17
Real-time Price: $0.900 info
Change: -$0.270 (-23%) info
Market Cap: $39.962M info
ELUT
Mar 04, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.17
Real-time Price: $0.900 info
Change: -$0.270 (-23%) info
Market Cap: $39.962M info
ELUT
Jan 12, 2026, 8:51 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.780
Real-time Price: $0.900 info
Change: +$0.120 (+15%) info
Market Cap: $39.962M info
ELUT
Jan 02, 2026, 8:46 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.7282
Real-time Price: $0.900 info
Change: +$0.1718 (+24%) info
Market Cap: $39.962M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets